What is the Return on Assets (ROA) of AnGes this year?
The Return on Assets (ROA) of AnGes is -6.03 undefined this year.
AnGes ROA 2025
AnGes ROA
-6.03
Ticker
4563.T
ISIN
JP3127700007
WKN
779518
In 2025, AnGes's return on assets (ROA) was -6.03, a 2,240.56% increase from the -0.26 ROA in the previous year.
AnGes Aktienanalyse
What does AnGes do?
AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding AnGes's Return on Assets (ROA)
AnGes's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing AnGes's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider AnGes's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in AnGes’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about AnGes stock
What was the ROA of AnGes compared to the previous year?
The ROA of AnGes has increased by 2,240.56% compared to the previous year.
What consequences do high ROA have for investors of AnGes?
A high ROA is advantageous for investors of AnGes, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in AnGes?
A low ROA can be unfavorable for investors of AnGes as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of AnGes affect the company?
An increase in ROA of AnGes can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of AnGes impact the company?
A reduction in the ROA of AnGes can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of AnGes?
Some factors that can influence the ROA of AnGes include revenue, operating costs, asset structure, and industry average.
Why is the ROA of AnGes important for investors?
The ROA of AnGes is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can AnGes take to improve ROA?
To improve ROA, AnGes can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does AnGes pay?
Over the past 12 months, AnGes paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnGes is expected to pay a dividend of 0 JPY.
What is the dividend yield of AnGes?
The current dividend yield of AnGes is .
When does AnGes pay dividends?
AnGes pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AnGes?
AnGes paid dividends every year for the past 0 years.
What is the dividend of AnGes?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is AnGes located?
AnGes is assigned to the 'Health' sector.
Wann musste ich die Aktien von AnGes kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AnGes from 8/11/2025 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 8/11/2025.
When did AnGes pay the last dividend?
The last dividend was paid out on 8/11/2025.
What was the dividend of AnGes in the year 2024?
In the year 2024, AnGes distributed 0 JPY as dividends.
In which currency does AnGes pay out the dividend?
The dividends of AnGes are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AnGes
Our stock analysis for AnGes Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnGes Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
